Clinical Trials · NCT00128232
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis
- Enrollment
- 100
- Start date
- Dec 2002
- Locations
- See registry
- Primary endpoint
- Mean GH and IGF-I at baseline, week 12, 24 and 48